Lannett CO Inc LCI
We take great care to ensure that the data presented and summarized in this overview for LANNETT CO INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LCI
View allLatest Institutional Activity in LCI
Top Purchases
Top Sells
About LCI
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's product portfolio includes Amphetamine IR tablets, Amphetamine ER capsules, Dicyclomine tablets, Fluphenazine tablets, Levothyroxine capsules, Methylphenidate CD capsules, Methylphenidate ER, Posaconazole DR tablets, Probenecid tablets, and Verapamil SR tablets, as well as Numbrino nasal solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, Sinotherapeutics, Respirent Pharmaceuticals Co., Ltd., HEC Pharm Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.
Insider Transactions at LCI
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 17
2022
|
John C Chapman Director |
BUY
Open market or private purchase
|
Direct |
20,000
+10.29%
|
$0
$0.51 P/Share
|
Nov 10
2022
|
Timothy C Crew Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+2.42%
|
$0
$0.48 P/Share
|
Nov 10
2022
|
Patrick G Lepore Director |
BUY
Open market or private purchase
|
Direct |
100,000
+14.55%
|
$0
$0.49 P/Share
|
Sep 14
2022
|
Melissa Rewolinski Director |
BUY
Open market or private purchase
|
Direct |
31,159
+25.04%
|
$0
$0.49 P/Share
|
Sep 07
2022
|
John Kozlowski VP of Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
775
-0.58%
|
$0
$0.47 P/Share
|
Sep 07
2022
|
John Abt Chief Quality and Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
950
-0.79%
|
$0
$0.47 P/Share
|
Jul 31
2022
|
John Kozlowski VP of Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,114
-5.52%
|
$0
$0.58 P/Share
|
Jul 31
2022
|
Samuel H Israel Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,154
-6.09%
|
$0
$0.58 P/Share
|
Jul 31
2022
|
Timothy C Crew Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
19,368
-3.18%
|
$0
$0.58 P/Share
|
Jul 31
2022
|
Maureen Cavanaugh Senior Vice President and CCOO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,656
-3.78%
|
$0
$0.58 P/Share
|
Jul 31
2022
|
John Abt Chief Quality and Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
3,924
-3.17%
|
$0
$0.58 P/Share
|
Jul 29
2022
|
John Kozlowski VP of Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,330
-2.21%
|
$0
$0.58 P/Share
|
Jul 29
2022
|
Samuel H Israel Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,465
-3.17%
|
$0
$0.58 P/Share
|
Jul 29
2022
|
Timothy C Crew Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,227
-1.49%
|
$0
$0.58 P/Share
|
Jul 29
2022
|
Maureen Cavanaugh Senior Vice President and CCOO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,042
-1.99%
|
$0
$0.58 P/Share
|
Jul 29
2022
|
John Abt Chief Quality and Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,798
-1.43%
|
$0
$0.58 P/Share
|
Jul 27
2022
|
John Kozlowski VP of Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,096
-4.51%
|
$0
$0.57 P/Share
|
Jul 27
2022
|
Timothy C Crew Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,384
-2.58%
|
$0
$0.57 P/Share
|
Jul 27
2022
|
Maureen Cavanaugh Senior Vice President and CCOO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,784
-3.04%
|
$0
$0.57 P/Share
|
Jul 27
2022
|
Samuel H Israel Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,589
-4.75%
|
$0
$0.57 P/Share
|